Prevencio has announced data demonstrating its HART PAD test accurately diagnoses peripheral arterial disease (PAD) in diabetes mellitus patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these important findings, presented at the 2018 European Society of Cardiology Congress (ESC; 25–29 August, Munich, Germany), could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive, and invasive tests.
The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June 2018, demonstrating Prevencio’s HART CAD and HART CVE tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in diabetes mellitus patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.
In this study, researchers assessed the company’s AI-driven HART PAD diagnostic test on patients enrolled in Massachusetts General Hospital’s catheter sampled blood archive in cardiovascular disease (CASABLANCA) study. The HART PAD test algorithmically assesses six biomarkers linked to atherosclerosis, as well as a patient’s history of hypertension. In patients with diabetes mellitus, the HART PAD panel had excellent performance for diagnosis of PAD. Using a 5-point score, a score of 1 had a 100% Negative Predictive Value (NPV) and a score of 5 had a 95% Positive Predictive Value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularisation in patients with PAD. These results were comparable to those patients without diabetes mellitus.
Principal investigator James L Januzzi, practicing cardiologist atMassachusetts General Hospital and professor of Medicine at Harvard Medical School, says, “The HART PAD test may allow for the diagnosis and treatment of many more patients with currently undetected PAD. In the clinical setting, these findings could assist physicians to identify peripheral arterial disease earlier, provide guideline-recommended care, and monitor at-risk patients for vascular complications. We believe HART tests could also play an important role in identifying high risk patients for enrolment in clinical trials, thereby saving time and lowering overall trial costs.”
PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with diabetes mellitus are at substantial risk of developing PAD. Patients with PAD have increased risk of CAD, heart attack, or stroke, and, if left untreated, PAD can lead to foot or leg amputation. Prevencio has also developed the HART AMP to accurately predict a patient’s risk for amputation.
According to the Centers for Disease Control and Prevention, more than 30 million people in the USA have diabetes and the total direct and indirect costs associated with patients diagnosed with diabetes total US$327 billion annually.
“This ESC presentation adds to the growing volume of presented and published scientific literature supporting the accuracy and clinical benefit of our novel HART tests,” says Rhonda Rhyne, Prevencio’s CEO. “The potential of our HART tests to fulfil the urgent need for alternative, reliable, and cost-effective cardiovascular diagnostic and monitoring solutions is encouraging, especially for diabetic patients. For this underserved patient population, PAD and CAD can result in significant morbidity and mortality due to lack of diagnosis and timely treatment.”